Your browser doesn't support javascript.
loading
Paired heavy and light chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responses
Bailey B Banach; Gabriele Cerutti; Ahmed S Fahad; Chen-Hsiang Shen; Matheus Oliveira de Souza; Phinikoula S Katsamba; Yaroslav Tsybovsky; Pengfei Wang; Manoj S Nair; Yaoxing Huang; Irene M Francino Urdaniz; Paul J Steiner; Matias Gutierrez-Gonzalez; Lihong Liu; Sheila N Lopez Acevedo; Alexandra Nazzari; Jacy R Wolfe; Yang Luo; Adam S Olia; I-Ting Teng; Jian Yu; Tongqing Zhou; Eswar R Reddem; Jude Bimela; Xiaoli Pan; Bharat Madan; Amy D Laflin; Rajani Nimrania; Kwon-Tung Yuen; Timothy A Whitehead; David D Ho; Peter D Kwong; Lawrence Shapiro; Brandon J DeKosky.
Afiliação
  • Bailey B Banach; Bioengineering Graduate Program, University of Kansas, Lawrence, KS 66045, USA.
  • Gabriele Cerutti; Department of Biochemistry and Molecular Biophysics, Columbia University, New York, NY 10032, USA. Zuckerman Mind Brain Behavior Institute, Columbia University,
  • Ahmed S Fahad; Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS 66045, USA.
  • Chen-Hsiang Shen; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Matheus Oliveira de Souza; Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS 66045, USA.
  • Phinikoula S Katsamba; Department of Biochemistry and Molecular Biophysics, Columbia University, New York, NY 10032, USA. Zuckerman Mind Brain Behavior Institute, Columbia University,
  • Yaroslav Tsybovsky; Electron Microscopy Laboratory, Cancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederi
  • Pengfei Wang; Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA.
  • Manoj S Nair; Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA.
  • Yaoxing Huang; Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA.
  • Irene M Francino Urdaniz; Department of Chemical and Biological Engineering, University of Colorado, Boulder, CO, 80305, USA.
  • Paul J Steiner; Department of Chemical and Biological Engineering, University of Colorado, Boulder, CO, 80305, USA.
  • Matias Gutierrez-Gonzalez; Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS 66045, USA.
  • Lihong Liu; Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA.
  • Sheila N Lopez Acevedo; Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS 66045, USA.
  • Alexandra Nazzari; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Jacy R Wolfe; Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS 66045, USA.
  • Yang Luo; Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA.
  • Adam S Olia; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • I-Ting Teng; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Jian Yu; Department of Biochemistry and Molecular Biophysics, Columbia University, New York, NY 10032, USA. Aaron Diamond AIDS Research Center, Columbia University Vagel
  • Tongqing Zhou; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Eswar R Reddem; Department of Biochemistry and Molecular Biophysics, Columbia University, New York, NY 10032, USA. Zuckerman Mind Brain Behavior Institute, Columbia University,
  • Jude Bimela; Department of Biochemistry and Molecular Biophysics, Columbia University, New York, NY 10032, USA. Zuckerman Mind Brain Behavior Institute, Columbia University,
  • Xiaoli Pan; Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS 66045, USA.
  • Bharat Madan; Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS 66045, USA.
  • Amy D Laflin; Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS 66045, USA.
  • Rajani Nimrania; Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS 66045, USA.
  • Kwon-Tung Yuen; State Key Laboratory for Emerging Infectious Diseases, Department of Microbiology, Carol Yu Centre for Infection, Li Ka Shing Faculty of Medicine, The Universit
  • Timothy A Whitehead; Department of Chemical and Biological Engineering, University of Colorado, Boulder, CO, 80305, USA.
  • David D Ho; Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA.
  • Peter D Kwong; Department of Biochemistry and Molecular Biophysics, Columbia University, New York, NY 10032, USA. Vaccine Research Center, National Institute of Allergy and In
  • Lawrence Shapiro; Department of Biochemistry and Molecular Biophysics, Columbia University, New York, NY 10032, USA. Aaron Diamond AIDS Research Center, Columbia University Vagel
  • Brandon J DeKosky; Bioengineering Graduate Program, University of Kansas, Lawrence, KS 66045, USA. Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS 66045
Preprint em En | PREPRINT-BIORXIV | ID: ppbiorxiv-424987
Artigo de periódico
Um artigo publicado em periódico científico está disponível e provavelmente é baseado neste preprint, por meio do reconhecimento de similaridade realizado por uma máquina. A confirmação humana ainda está pendente.
Ver artigo de periódico
ABSTRACT
Understanding protective mechanisms of antibody recognition can inform vaccine and therapeutic strategies against SARS-CoV-2. We discovered a new antibody, 910-30, that targets the SARS-CoV-2 ACE2 receptor binding site as a member of a public antibody response encoded by IGHV3-53/IGHV3-66 genes. We performed sequence and structural analyses to explore how antibody features correlate with SARS-CoV-2 neutralization. Cryo-EM structures of 910-30 bound to the SARS-CoV-2 spike trimer revealed its binding interactions and ability to disassemble spike. Despite heavy chain sequence similarity, biophysical analyses of IGHV3-53/3-66 antibodies highlighted the importance of native heavylight pairings for ACE2 binding competition and for SARS-CoV-2 neutralization. We defined paired heavylight sequence signatures and determined antibody precursor prevalence to be ~1 in 44,000 human B cells, consistent with public antibody identification in several convalescent COVID-19 patients. These data reveal key structural and functional neutralization features in the IGHV3-53/3-66 public antibody class to accelerate antibody-based medical interventions against SARS-CoV-2. HighlightsO_LIA molecular study of IGHV3-53/3-66 public antibody responses reveals critical heavy and light chain features for potent neutralization C_LIO_LICryo-EM analyses detail the structure of a novel public antibody class member, antibody 910-30, in complex with SARS-CoV-2 spike trimer C_LIO_LICryo-EM data reveal that 910-30 can both bind assembled trimer and can disassemble the SARS-CoV-2 spike C_LIO_LISequence-structure-function signatures defined for IGHV3-53/3-66 class antibodies including both heavy and light chains C_LIO_LIIGHV3-53/3-66 class precursors have a prevalence of 144,000 B cells in healthy human antibody repertoires C_LI
Licença
cc_no
Texto completo: 1 Coleções: 09-preprints Base de dados: PREPRINT-BIORXIV Tipo de estudo: Observational_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Preprint
Texto completo: 1 Coleções: 09-preprints Base de dados: PREPRINT-BIORXIV Tipo de estudo: Observational_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Preprint